3.1400 +0.04 (1.29%)
After hours: 5:36PM EDT
|Bid||3.1000 x 1800|
|Ask||3.1400 x 1300|
|Day's Range||3.0100 - 3.6400|
|52 Week Range||1.9200 - 9.5000|
|Beta (5Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 29, 2020 - Jun 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
RUTHERFORD, N.J., June 01, 2020 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced.
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. For example, we...
RUTHERFORD, N.J., Feb. 20, 2020 -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and.
RUTHERFORD, N.J., Nov. 20, 2019 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced.
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. For example, we sympathize with...
Cancer Genetics, Inc. (CGIX), a leader in proprietary preclinical test systems supporting drug discovery and development at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers, today announced, among others, the completion of several strategic transactions. As the result of the previously announced sale of the company’s BioPharma business to Interpace Diagnostics Group, Inc. (IDXG) or its affiliate, IDXG or its affiliate paid approximately $6 million in cash to CGIX on October 24, 2019, as partial settlement of a promissory note in the original face amount of approximately $7.7 million due to CGIX.
Cancer Genetics, Inc. (CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding common stock. The reverse stock split is intended to increase the per share trading price of Cancer Genetics’ common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market (Rule 5550(a)(2)). Cancer Genetics’ common stock will continue to trade on The Nasdaq Capital Market under the symbol “CGIX” and under a new CUSIP number, 13739U203.
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with the Company’s July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX). The condition surrounding the second tranche financing was approved by Interpace shareholders which was obtained at the Annual Shareholder Meeting on October 10, 2019.
RUTHERFORD, N.J., Aug. 20, 2019 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Capricor Therapeutics, Inc. (NASDAQ: CAPR ...
Cancer Genetics (NASDAQ: CGIX ) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG ) said it purchased the Biopharma Services unit of the Cancer Genetics. Interpace Diagnostics ...
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”), announced today that it has acquired assets and certain liabilities constituting the Biopharma Services business of Cancer Genetics, Inc. (CGIX) (the “BioPharma Business”) for approximately $23.5 million subject to certain adjustments. The acquisition is expected to create a leading oncology testing and service company in the clinical diagnostic and Biopharma markets, leveraging sophisticated assays, novel algorithms and custom service capabilities across the continuum of oncology from precancerous assessment to drug discovery and clinical trial support. In conjunction with this acquisition Ampersand Capital Partners, one of the leading private equity firms in the diagnostic/biopharma sector, agreed to invest $27M in Interpace in two tranches of newly issued convertible preferred stock, a portion of which will be subject to approval by Interpace’s shareholders.
Innovate Biopharmaceuticals, Inc. (INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment of Ed Sitar as its Chief Financial Officer commencing on July 1, 2019. With an expanded management team, Innovate intends to focus on non-dilutive sources of capital to further develop its pipeline, including out-licensing of (i) selective ex-US rights to INN-202 for celiac disease and (ii) Innovate’s earlier clinical stage pipeline of drug product candidates. In addition, Innovate intends to suspend future sales of shares under its “at-the-market” established pursuant to its common stock sales agreement with H.C. Wainwright & Co., LLC and Ladenburg Thalmann & Co. Inc.
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.